Literature DB >> 8840853

Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease.

R Miccoli1, A Bertolotto, R Navalesi, L Odoguardi, A Boni, J Wessling, H Funke, H Wiebusch, A Eckardstein, G Assmann.   

Abstract

BACKGROUND: The concentration of HDL cholesterol is inversely correlated with the risk of coronary heart disease (CHD). Some rare mutations in the apolipoprotein (apo) A-I gene are associated with low levels of HDL cholesterol. Their association with cardiovascular risk is controversial. METHODS AND
RESULTS: We studied the molecular defects underlying corneal opacities and absence of HDL cholesterol in three brothers and a sister. In a family study, the importance of these defects for lipid metabolism and manifestation of coronary heart disease was investigated. The frequency of these apo A-I defects was assessed by genotype and phenotype analysis of 477 DNA- and plasma samples, respectively, from the population. The four patients were compound heterozygotes for a null allele and a missense mutation in the apo A-I gene that leads to a leucine-->arginine substitution at residue 141 [apo A-I(L141R)Pisa]. Heterozygotes for either the null allele or the structural variant had half-normal concentrations of HDL cholesterol and apo A-I compared with unaffected family members. Apo A-I(L141R)Pisa was detected in one more unrelated subject. Coronary angiography of the four compound heterozygotes revealed the presence of CHD in all male patients, whose ages ranged between 45 and 52 years. They presented with additional risk factors, including elevated LDL cholesterol levels, obesity, and arterial hypertension. Despite complete HDL deficiency and hypercholesterolemia, CHD was absent in the 51-year-old premenopausal sister.
CONCLUSIONS: Apo A-I deficiency may lead to premature atherosclerosis if present in conjunction with additional cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840853     DOI: 10.1161/01.cir.94.7.1622

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice.

Authors:  O Stein; Y Dabach; G Hollander; M Ben-Naim; G Halperin; J L Breslow; Y Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice.

Authors:  Sean A Wiltshire; Eduardo Diez; Qianqian Miao; Marie-Pierre Dubé; Mireille Gagné; Olivier Paquette; Ronald G Lafrenière; Momar Ndao; Lawrence W Castellani; Emil Skamene; Silvia M Vidal; Anny Fortin
Journal:  Physiol Genomics       Date:  2012-07-17       Impact factor: 3.107

Review 3.  [Inborn errors of high-density lipoprotein metabolism].

Authors:  Arnold von Eckardstein
Journal:  Internist (Berl)       Date:  2019-12       Impact factor: 0.743

4.  Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.

Authors:  Georgios Koukos; Angeliki Chroni; Adelina Duka; Dimitris Kardassis; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

5.  Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations.

Authors:  Monica Gomaraschi; Laura Obici; Sara Simonelli; Gina Gregorini; Alessandro Negrinelli; Giampaolo Merlini; Guido Franceschini; Laura Calabresi
Journal:  Clin Chim Acta       Date:  2011-03-31       Impact factor: 3.786

6.  Re-sequencing of the APOAI promoter region and the genetic association of the -75G > A polymorphism with increased cholesterol and low density lipoprotein levels among a sample of the Kuwaiti population.

Authors:  Suzanne A Al-Bustan; Ahmad E Al-Serri; Babitha G Annice; Majed A Alnaqeeb; Ghada A Ebrahim
Journal:  BMC Med Genet       Date:  2013-09-12       Impact factor: 2.103

7.  Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach.

Authors:  Christiane L Haase; Ruth Frikke-Schmidt; Børge G Nordestgaard; Anne Tybjærg-Hansen
Journal:  PLoS Genet       Date:  2012-11-29       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.